Treatment of acromegaly in Aarhus University Hospital: A retrospective investigation of the period from 1994 to 2004;Behandling af akromegali på Århus Universitetshospital: En retrospektiv opgørelse fra perioden 1994-2004

Ugeskrift for Laeger

Volumn 169, Issue 10, 2007, Pages 907-910

  Madsen, Michael ^a   Matthiesen, Esben Boll ^a   Poulsen, Per Løgstrup ^a   Weeke, Jørgen ^a   Astrup, Jens ^a   Jørgensen, Jens Otto Lunde ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; SOMATOMEDIN C; SOMATOSTATIN;

ACROMEGALY; ADENOMA; ADULT; AGED; ARTICLE; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HYPOPHYSIS TUMOR; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ACROMEGALY; ADENOMA; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; RETROSPECTIVE STUDIES; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 33947161865     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Holdaway IM, Rajasoorya CR, Gamble GD et al. Long term treatment outcome in acromegaly. Growth Horm IGF Res 2003;13:185-92.
2. Swearingen B, Barker FG, Katznelson L et al. Long-term mortality after trans-sphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-26.
3. AACE Acromegaly Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practicew for the diagnosis and treatment of acromegaly. Endocr Pract 2004;10:213-25.
4. Freda PU, Katznelson L, van der Lely AJ et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005;90:4465-73.
5. Conceicao FL, Fisker S, Christiansen JS et al. Biochemical definitions of disease activity in acromegaly. Growth Horm IGF Res 2003;13:98-103.
6. Freda PU. Current concepts in the biochemical assessment of the patient with acromegaly. Growth Horm IGF Res 2003;13:171-84.
7. Murray RD, Kim K, Ren SG et al. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest 2004;114:349-56.
8. Kopchick JJ, Parkinson C, Stevens EC et al. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 2002;23:623-46.
9. Melmed S, Sternberg R, Cook D et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005;90:4405-10.
10. Jorgensen JO, Feldt-Rasmussen U, Frystyk J et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 2005;90:5627-31.
11. Feenstra J, de Herder WW, ten Have SM et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005;365:1644-6.